Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep 15;8(9):15302-7.
eCollection 2015.

Galectin-3 mediates the effect of PDGF on pulmonary arterial hypertension

Shaomei Guo  1 , Ziming Feng  2
Affiliations

Galectin-3 mediates the effect of PDGF on pulmonary arterial hypertension

Shaomei Guo et al. Int J Clin Exp Med. .

Abstract

Aims: The present study aimed to perform in vitro experiments to investigate whether Galectin-3 (Gal-3) mediates the effect of platelet-derived growth factor (PDGF) on pulmonary arterial smooth muscle cells (PASMC) proliferation, apoptosis and migration, and to reveal the mechanism of how Gal-3 functions in the pathogenesis of pulmonary arterial hypertension (PAH).

Methods: Pulmonary arterial smooth muscle cells (PASMC) were treated with various concentration of PDGF for indicated times, and the expression of Gal-3 was analyzed by western blotting. Gal-3 siRNA was transfected into the PASMC to knock down endogenous Gal-3. MTT assay was performed to examine cell proliferation. Transwell-migration assay was used to determine cell migration ability. Cell apoptosis rate was determined by flow cytometric analysis.

Results: The result showed that the expression of Gal-3 protein was induced by PDGF in a dose- and a time-dependent manner. PDGF contributes to the progression of PAH by inducing cell proliferation and migration, as well as inhibiting cell apoptosis of PASMC. However, these effects of PDGF on PASMC were attenuated by Gal-3 knockdown.

Conclusion: The present study provided potential evidence about the role of Gal-3 in the pathophysiological mechanisms of PAH. This study firstly demonstrated that Gal-3 could be induced by PDGF in PASMC, and mediates the effect of PDGF on PASMC proliferation, apoptosis and migration, thus contributing to the pathogenesis of PAH.

Keywords: Galectin-3; platelet-derived growth factor; pulmonary arterial hypertension.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PDGF induced the expression of Gal-3 in PASMC. A. The dose-dependent effect of PDGF on Gal-3 protein expression. *P<0.05 and #P<0.01 compared with 0 ng/ml. B. The time-dependent effect of PDGF on Gal-3 protein expression. #P<0.01 compared with 0 h. Gal-3, Galectin-3; PDGF, platelet-derived growth factor.
Figure 2
Figure 2
Expression of Gal-3 protein in PASMC following treatment with PDGF and transfection of Gal-3 siRNA. Lane 1, Ctrl + NC; lane 2, Ctrl + Si; lane 3, PDGF + NC; lane 4, PDGF + Si. #P<0.01 compared with Ctrl + NC; $P<0.01 compared with PDGF + NC. Gal-3, Galectin-3; PDGF, platelet-derived growth factor; Ctrl, control; Si, siRNA.
Figure 3
Figure 3
Gal-3 mediates the effect of PDGF on PASMC proliferation. Gal-3, Galectin-3; PDGF, platelet-derived growth factor; Ctrl, control; Si, siRNA.
Figure 4
Figure 4
Gal-3 mediates the effect of PDGF on PASMC apoptosis. #P<0.01 compared with Ctrl + NC; $P<0.01 compared with PDGF + NC. Gal-3, Galectin-3; PDGF, platelet-derived growth factor; Ctrl, control; Si, siRNA.
Figure 5
Figure 5
Gal-3 mediates the effect of PDGF on PASMC migration. *P<0.05 compared with Ctrl + NC; &P<0.05 compared with PDGF + NC. Gal-3, Galectin-3; PDGF, platelet-derived growth factor; Ctrl, control; Si, siRNA.
See this image and copyright information in PMC

References

    1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111–117. - PubMed
    1. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G ESC Committee for Practice Guidelines (CPG) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J. 2009;30:2493–2537. - PubMed
    1. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:5S–12S. - PubMed
    1. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012;142:448–456. - PubMed
    1. Funasaka T, Raz A, Nangia-Makker P. Galectin-3 in angiogenesis and metastasis. Glycobiology. 2014;24:886–891. - PMC - PubMed

LinkOut - more resources